Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Total revenues	$ 35,340	$ 18,032
Cost of product revenue	8,521	4,218
Research and development	19,500	11,571
Selling, general and administrative	15,705	11,398
Total costs and operating expenses	43,726	27,187
Income (loss) from operations	(8,386)	(9,155)
Unallocated depreciation and amortization	(1,215)	(659)
Stock-based compensation	3,838	2,687
Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	33,099	14,229
Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	2,241	3,803
Operating Segments
Segment Reporting Information [Line Items]
Total revenues	35,340	18,032
Cost of product revenue	8,521	4,218
Research and development	18,468	11,049
Selling, general and administrative	4,261	3,418
Total costs and operating expenses	31,250	18,685
Income (loss) from operations	4,090	(653)
Stock-based compensation	3,838	2,687
Operating Segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	33,099	14,229
Cost of product revenue	8,521	4,218
Research and development	6,122	6,444
Selling, general and administrative	3,541	2,818
Total costs and operating expenses	18,184	13,480
Income (loss) from operations	14,915	749
Stock-based compensation	1,487	994
Operating Segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	2,241	3,803
Cost of product revenue	0	0
Research and development	12,346	4,605
Selling, general and administrative	720	600
Total costs and operating expenses	13,066	5,205
Income (loss) from operations	(10,825)	(1,402)
Stock-based compensation	410	238
Corporate
Segment Reporting Information [Line Items]
Total costs and operating expenses	(11,205)	(7,728)
Unallocated depreciation and amortization	(1,232)	(685)
Income (loss) before income taxes	(8,347)	(9,066)
Stock-based compensation	1,941	1,455
Product revenue
Segment Reporting Information [Line Items]
Total revenues	30,690	10,226
Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	30,690	10,226
Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0
Product revenue | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	30,690	10,226
Product revenue | Operating Segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	30,690	10,226
Product revenue | Operating Segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0
Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	4,650	7,806
Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	2,409	4,003
Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	2,241	3,803
Research and development revenue | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	4,650	7,806
Research and development revenue | Operating Segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	2,409	4,003
Research and development revenue | Operating Segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	$ 2,241	$ 3,803